Tech Company Financing Transactions
Acura Pharmaceuticals Funding Round
Acura Pharmaceuticals closed a $450 thousand venture capital round on 8/16/2006. Investors included Care Capital, EW Healthcare Partners and Galen Partners.
Transaction Overview
Company Name
Announced On
8/16/2006
Transaction Type
Debt
Amount
$450,000
Round
Undisclosed
Proceeds Purpose
The Company will utilize the net proceeds from the Loan to continue funding product development and licensing activities relating to OxyADF" tablets and other product candidates utilizing its Aversion Technology.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
616 North North Ct. 120
Palatine, IL 60067
USA
Palatine, IL 60067
USA
Phone
Website
Email Address
Overview
Acura and King are developing Acurox (oxycodone HCl) Tablets (without niacin) intended to relieve moderate to severe pain.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Jones
Chief Financial Officer
Peter Clemens
Controller
Robert Seiser
Browse more venture capital transactions:
Prev: 8/15/2006: Bolt Solutions venture capital transaction
Next: 8/16/2006: TolerRx venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs